União Europeia - português - EMA (European Medicines Agency)

swedish orphan biovitrum ab (publ) - emapalumab - immune system diseases - gamifant is indicated for the treatment of paediatric patients aged under 18 years with primary haemophagocytic lymphohistiocytosis (hlh).

União Europeia - português - EMA (European Medicines Agency)

astrazeneca ab - durvalumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - non-small cell lung cancer (nsclc)imfinzi as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (nsclc) in adults whose tumours express pd-l1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5. imfinzi in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic nsclc with no sensitising egfr mutations or alk positive mutations. small cell lung cancer (sclc)imfinzi in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (es-sclc). biliary tract cancer (btc)imfinzi in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (btc). hepatocellular carcinoma (hcc)imfinzi in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc).

União Europeia - português - EMA (European Medicines Agency)

roche registration limited - emicizumab - hemofilia a - anti-hemorrágicos - hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia a (congenital factor viii deficiency):with factor viii inhibitorswithout factor viii inhibitors who have:severe disease (fviii < 1%)moderate disease (fviii ≥ 1% and ≤ 5%) with severe bleeding phenotype. hemlibra pode ser usado em todos os grupos de idade.

União Europeia - português - EMA (European Medicines Agency)

novartis europharm limited - omalizumab - asthma; urticaria - medicamentos para obstrutiva, doenças das vias respiratórias, - alérgica asthmaxolair é indicado em adultos, adolescentes e crianças (de 6 a.

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

astrazeneca do brasil ltda - durvalumabe -

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

novartis biociencias s.a - omalizumabe - outros antialergicos

Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

produtos roche quÍmicos e farmacÊuticos s.a. - emicizumabe - outros hemostÁticos sistÊmicos

União Europeia - português - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, hepatocellular - agentes antineoplásicos - imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (hcc). imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

União Europeia - português - EMA (European Medicines Agency)

astrazeneca ab - tremelimumab - carcinoma, pulmão de células não pequenas - agentes antineoplásicos - tremelimumab astrazeneca in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (nsclc) with no sensitising egfr mutations or alk positive mutations.

Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

baxalta innovations gmbh - factores de coagulação do sangue - pó e solvente para solução para perfusão - 1000 u/20 ml - actividade de bypass do inibidor do factor viii 1000 u ; proteínas do plasma humano proteínas do plasma humano - factor viii inhibitor bypassing activity - derivado do sangue e plasma humano - duração do tratamento: curta ou média duração